Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL) |
| Type de publication | Journal Article |
| Year of Publication | 2019 |
| Auteurs | Hofmans M, Suciu S, Ferster A, Van Vlierberghe P, Mazingue F, Sirvent N, Costa V, Yakouben K, Paillard C, Uyttebroeck A, Plantaz D, Plat G, Simon P, Millot F, Poiree M, Bosch JVan der We, Piette C, Minckes O, Rohrlich P, Girard S, Cave H, Bertrand Y, De Moerloose B |
| Journal | BRITISH JOURNAL OF HAEMATOLOGY |
| Volume | 186 |
| Pagination | 741-753 |
| Date Published | SEP |
| Type of Article | Article |
| ISSN | 0007-1048 |
| Mots-clés | asparaginase, childhood leukaemia, cranial radiotherapy, EORTC, T-cell acute lymphoblastic leukaemia |
| Résumé | {Outcomes in childhood T-cell acute lymphoblastic leukaemia (T-ALL) are steadily improving due to intensive therapy. Between 1989 and 2008, 599 children with newly diagnosed T-ALL were enrolled in two successive European Organization for Research and Treatment of Cancer - Children's Leukaemia Group trials (58881 and 58951), both based on the Berlin-Frankfurt-Munster protocol and without cranial irradiation. In the latter trial induction chemotherapy was intensified. The most important randomizations were Medac Escherichia coli asparaginase versus Erwinia asparaginase in trial 58881, and dexamethasone (6 mg/m(2)/day) versus prednisolone (60 mg/m(2)/day) and prolonged versus conventional asparaginase duration in trial 58951. 8-year event-free survival (EFS) increased from 65 center dot 1% to 74 center dot 0% in trial 58951. Improvement was most profound for patients with white blood cell (WBC) counts E. coli asparaginase was associated with longer EFS [hazard ratio (HR) 0 center dot 54 |
| DOI | 10.1111/bjh.15983 |